PLX Key Statistics, Chart & Performance
The current stock price of PLX is 2.04 USD. In the past month the price increased by 15.91%. In the past year, price decreased by -8.11%.
PLX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PLX. When comparing the yearly performance of all stocks, PLX turns out to be only a medium performer in the overall market: it outperformed 40.49% of all stocks.
PLX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PLX. PLX has only an average score on both its financial health and profitability.
PLX Financial Highlights
Over the last trailing twelve months PLX reported a non-GAAP Earnings per Share(EPS) of 0.07. The EPS increased by 153.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.13% | ||
| ROA | 8% | ||
| ROE | 12.57% | ||
| Debt/Equity | 0 |
PLX Forecast & Estimates
5 analysts have analysed PLX and the average price target is 12.75 USD. This implies a price increase of 525% is expected in the next year compared to the current price of 2.04.
For the next year, analysts expect an EPS growth of -15.83% and a revenue growth 12.02% for PLX
PLX Ownership
PLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About PLX
Company Profile
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 207 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Company Info
PROTALIX BIOTHERAPEUTICS INC
2 University Plaza, Suite 100
Hackensack NEW JERSEY 07601 US
CEO: Dror Bashan
Employees: 207
Phone: 12016969345
PROTALIX BIOTHERAPEUTICS INC / PLX FAQ
What does PROTALIX BIOTHERAPEUTICS INC do?
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. The company is headquartered in Hackensack, New Jersey and currently employs 207 full-time employees. The company went IPO on 2010-09-06. The firm is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Can you provide the latest stock price for PROTALIX BIOTHERAPEUTICS INC?
The current stock price of PLX is 2.04 USD. The price decreased by -0.97% in the last trading session.
Does PLX stock pay dividends?
PLX does not pay a dividend.
What is the ChartMill technical and fundamental rating of PLX stock?
PLX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for PLX stock?
5 analysts have analysed PLX and the average price target is 12.75 USD. This implies a price increase of 525% is expected in the next year compared to the current price of 2.04.
When does PROTALIX BIOTHERAPEUTICS INC (PLX) report earnings?
PROTALIX BIOTHERAPEUTICS INC (PLX) will report earnings on 2026-03-16, before the market open.
What is the outstanding short interest for PROTALIX BIOTHERAPEUTICS INC?
The outstanding short interest for PROTALIX BIOTHERAPEUTICS INC (PLX) is 6.11% of its float.